Open AccessPrognostic Value of HER-2/neu Gene Amplification in Epithelial Ovarian Carcinoma
Author(s) -
Sangeeta Pankaj,
Jaya Kumari,
Vijayanand Choudhary,
Anita Kumari,
Simi Kumari,
Anjili Kumari,
Syed Nazneen,
Richa Madhawi,
Shishir Kumar
Publication year - 2018
Publication title -
journal of obstetrics and gynecology of india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.313
H-Index - 17
eISSN - 0971-9202
pISSN - 0975-6434
DOI - 10.1007/s13224-018-1186-5
Subject(s) - medicine , immunohistochemistry , ovarian cancer , epidermal growth factor receptor , biomarker , oncology , cancer , progesterone receptor , ovarian carcinoma , epidermal growth factor , cancer research , breast cancer , receptor tyrosine kinase , receptor , estrogen receptor , biology , biochemistry
Human epidermal growth factor receptor 2 (HER2) has tyrosine kinase activity and is a member of the epidermal growth factor receptor family. This initiates a variety of signal for pathways which leads to cell proliferation and tumourigenesis. In approximately 15-30% of breast cancers and 10-30% of gastric/gastroesophageal cancers, amplification or overexpression of HER2 occurs, and it serves as a prognostic and predictive biomarker. HER-2/neu is one of the most frequently studied molecular biological parameters in epithelial ovarian cancer (EOC), but its prognostic impact has not been fully assessed. The objective of the current study was firstly to analyse the presence of HER-2 overexpression in EOC patients and secondly to evaluate association between human epidermal growth factor receptor 2 (HER-2/neu) expression and progression-free survival in patients with EOC.